Welcome to our dedicated page for OPNT news (Ticker: OPNT), a resource for investors and traders seeking the latest updates and insights on OPNT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OPNT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OPNT's position in the market.
Opiant Pharmaceuticals (NASDAQ: OPNT) announced its Q1 2022 financial results, reporting revenues of $4.5 million, a decrease from $6.4 million in Q1 2021. Revenue from its license agreement with Emergent BioSolutions for NARCAN® Nasal Spray was $2.2 million, down from $4.3 million due to a reduced royalty rate triggered by the Generic Reduction Clause. The company reported a net loss of approximately $12.2 million or $2.43 per share. However, Opiant is on track to submit a New Drug Application for OPNT003, its nasal nalmefene treatment for opioid overdose, in H2 2022.
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will release its financial results for Q1 2022 on May 10, 2022. The announcement will occur after market close, followed by a conference call at 4:30 PM ET. Investors can access the call at 1-877-407-0792 (U.S.) or 1-201-689-8263 (International) and join the live webcast online. Opiant is known for developing NARCAN® Nasal Spray and is focused on creating new treatments for addiction and drug overdose.
Opiant Pharmaceuticals (NASDAQ: OPNT) has announced that a press release issued on April 29, 2022, claiming a partnership with Hikma Pharmaceuticals is false. Opiant confirmed it had no involvement or knowledge of the release distributed by Cision PR Newswire, which incorrectly stated a $225 million commercialization agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. Cision has issued a notice advising the public to disregard the false news. Opiant directs all inquiries regarding this matter to Cision.
Opiant Pharmaceuticals (NASDAQ: OPNT) announced positive topline results from a pharmacodynamic study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose. The study compared 3 mg nasal nalmefene with 4 mg nasal naloxone in reversing respiratory depression induced by remifentanil. OPNT003 not only met the primary endpoint of non-inferiority but also exhibited a nearly twofold greater reversal in respiratory depression at five minutes post-administration. The completion of this study concludes the planned clinical development program for OPNT003, with an NDA filing expected in the second half of 2022.
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q4 2021 revenues of $13.8 million, a 39% increase from Q4 2020, and full-year 2021 revenue of $47.8 million, up 61% year-over-year.
Full-year net income was $3.0 million, with $53 million in cash on hand. The company exceeded its royalty revenue guidance, achieving approximately $41 million for 2021.
Opiant's pipeline includes OPNT003, aimed at opioid overdose treatment, with a New Drug Application submission targeted for mid-2022, and a Phase 2 study for OPNT002 addressing Alcohol Use Disorder.
Opiant Pharmaceuticals (Nasdaq: OPNT) announced that CEO Dr. Roger Crystal will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference from March 15 to March 17, 2022. The chat is scheduled for March 16 at 2:40 PM ET, and management will also host 1-on-1 investor meetings. A webcast of the presentation will be available on the Opiant website. Opiant focuses on developing medications for addictions and drug overdose, including the well-known NARCAN® Nasal Spray.
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its fourth quarter 2021 financial results and pipeline updates on March 15, 2022, after market close. The management team will host a conference call at 4:30 p.m. ET that same day, which can be accessed via phone or live webcast. Opiant is known for developing NARCAN® Nasal Spray and is focused on creating new medications for addiction and overdose treatment.
Opiant Pharmaceuticals (NASDAQ: OPNT) announced positive topline results from a pharmacokinetic study for OPNT003, an investigational nasal nalmefene treatment for opioid overdose. Conducted with 23 healthy subjects, the study demonstrated rapid nasal absorption (Tmax 15 min), dose-proportional plasma concentrations, and a long plasma half-life (~11h). OPNT003 was safe and well tolerated. These findings support the upcoming New Drug Application (NDA) submission due to the FDA's request. The ongoing research also compares nasal nalmefene against nasal naloxone to enhance opioid overdose treatment.
Opiant Pharmaceuticals (NASDAQ: OPNT) announced a $2.2 million funding increase from BARDA to support OPNT003, a nasal nalmefene for opioid overdose treatment. This funding will aid clinical studies necessary for FDA submission. OPNT003 has shown promising results in pharmacodynamic studies against nasal naloxone. The project aligns with Opiant's mission to address the opioid crisis, exacerbated by synthetic opioids like fentanyl. Earlier BARDA awards totaling $8.1 million and a $7.4 million grant further support this initiative.
Opiant Pharmaceuticals has initiated a Phase 2 clinical trial for OPNT002, a nasal naltrexone treatment for Alcohol Use Disorder (AUD). The trial aims to determine if OPNT002 effectively reduces heavy drinking by assessing changes in WHO drinking risk levels. Target enrollment is approximately 300 patients, with results expected in 2023. This treatment approach focuses on harm reduction rather than complete abstinence, potentially increasing medication adherence among those with AUD.
FAQ
What is the market cap of OPNT (OPNT)?
